Ibritumomab tiuxetan

Identification

Name
Ibritumomab tiuxetan
Accession Number
DB00078 / 4Q52C550XK
Groups
Zevalin
Description

Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed towards the CD20 antigen, that is discovered at the floor of regular and malignant B lymphocytes. Ibritumomab is produced in chinese hamster ovary cells and consists of two murine gamma 1 heavy chains of 445 amino acids every and kappa mild chains of 213 amino acids each.

Pharmacology

Pharmacodynamics

Ibritumomab is a murine monoclonal antibody against CD20 that has been radiolabeled with yttrium-90.

Indication

For treatment of non-Hodgkin's lymphoma

Action

The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles.